NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

"Meanwhile, Merck & Co., Inc. (NYSE:MRK) and Moderna shared encouraging results on January 20 tied to their experimental personalized cancer vaccine. The companies said the vaccine, when combined with Keytruda, continued to lower the risk of recurrence or death in high-risk melanoma patients even five years after treatment began. In the mid-stage trial involving patients who had already undergone surgery, the combo reduced the risk of recurrence or death by 49% after five years, consistent with the strong three-year data released back in 2023."
You mean they were not building 100's of thousands of sq ft for DcVax ??